当前位置: 易推广 > 生物试剂/抗体/细胞 > 生化试剂 > 其他 > MedChemExpress > 产品展示 > MCE信号通路 > 蛋白酪氨酸激酶 > JI-101
JI-101
企业档案
会员类型:会员
已获得易推广信誉 等级评定
(0 -40)基础信誉积累,可浏览访问
(41-90)良好信誉积累,可接洽商谈
(91+ )优质信誉积累,可持续信赖
易推广会员:8年
最后认证时间:
注册号: 【已认证】
法人代表: 【已认证】
企业类型:生产商 【已认证】
注册资金:人民币万 【已认证】
产品数:91228
参观次数:11416116
联系我们
MedChemExpress
电话:021-58955995
联系人:客服部 (请说明是在易推广看到的!谢谢)
手机:13611715263
邮编:201203
邮箱:sales@medchemexpress.cn
地址:上海上海
详细内容
MCE 的所有产品仅用作科学研究或药证申报,我们不为任何个人用途提供产品和服务。
JI-101
CAS No. : 900573-88-8
MCE 站:JI-101
产品活性:JI-101是有口服活性的有抗癌活性的多靶点激酶抑制剂,可抑制 VEGFR2,PDGFRβ 和 EphB4。
研究领域:Protein Tyrosine Kinase/RTK
作用靶点:Ephrin Receptor | PDGFR | VEGFR
In Vitro: JI-101 is found to be stable in all preclinical and human liver microsomes. The % metabolized is ranged between 3.03-3.95 across the tested species liver microsomes. The % metabolized is relatively higher in mice liver microsomes followed by dog, human and rat liver microsomes.
In Vivo: JI-101excreted through bile along with its mono- and di-hydroxy metabolites. Following oral administration, JI-101 is rapidly absorbed, reaching Cmax within 2?h. The t1/2 of JI-101 with intravenous and oral route is found to be 1.75±0.79 and 2.66±0.13?h, respectively. The Cl and Vd by intravenous route for JI-101 are found to be 13.0±2.62?mL/min/kg and 2.11±1.42?L/kg, respectively. The tissue distribution of JI-101 is extensive with rapid and preferred uptake into lung tissue. Overall, the oral bioavailability of JI-101 is 55% and the primary route of elimination for JI-101 is feces.
相关产品:Covalent Screening Library Plus | Drug Repurposing Compound Library Plus | Clinical Compound Library Plus | Bioactive Compound Library Plus | Kinase Inhibitor Library | Protein Tyrosine Kinase Compound Library | Anti-Cancer Compound Library | Clinical Compound Library | Drug Repurposing Compound Library | Covalent Screening Library | Differentiation Inducing Compound Library | Reprogramming Compound Library | Anti-Cardiovascular Disease Compound Library | Orally Active Compound Library | Anti-Breast Cancer Compound Library | Anti-Pancreatic Cancer Compound Library | Anti-Blood Cancer Compound Library | Bevacizumab | Sunitinib | Imatinib | Semaxinib | SU 5402 | PD173074 | 5Z-7-Oxozeaenol | Cediranib | SAR131675 | Gandotinib | GW806742X | Tanshi IIA | PF-03814735 | NVP-BHG712 | Vatalanib dihydrochloride | CP-547632 | AST 487 | Tyrphostin A9 | Ki20227 | Motesanib | SU14813 | Ramucirumab | SU1498 | MAZ51 | PP121 | PP58 | Sennoside B
品牌介绍:
• MCE (MedChemExpress) 拥有数百种全球独家化合物,我们致力于为全球科研客户提供*新*全的高品质小分子活性化合物;
• 10,000 多种高选择性抑制剂、激动剂涉及各热门信号通路及疾病领域;
• 设有专业的实验中心和严格的质控、验证体系;
• 提供 LC/MS、NMR、HPLC、手性分析、元素分析等各项质检报告,确保产品的高纯度、高品质;
• 产品的生物活性多经各国客户实验验证;
• Nature, Cell, Science 等多种期刊及制药收录了MCE客户的科研成果;
• 专业团队跟踪*新的制药及生命科学研究进展,为您提供全球*新的活性化合物;
• 与世界各大制药公司及知名科研机构建立了长期的合作。
热门标签:ji101